| Will targeting insulin growth factor help us or hurt us?: An oncologist's perspective. | |
| | |
MedLine Citation:
|
PMID: 19896561 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The insulin/insulin growth factor (IGF) pathway is a critical mediator of longevity and aging. Efforts to extend longevity by altering the insulin/IGF pathway may have varying effects on other physiological processes. Reduced insulin/IGF levels may decrease the incidence of certain cancers as well as the risk of developing metastatic disease. However, it may also increase the risk of developing cardiovascular disease as well as cardiovascular related mortality. Pursuing the right insulin/IGF pathway targets will require striking a balance between inhibiting cancer cell development and progression and avoiding damage to tissues under normal insulin/IGF-mediated control. This review will discuss the roles of the insulin/IGF pathway in aging and longevity and the development of cancer cell metastasis and considerations in taking insulin/IGF directed targets to the oncology clinic. |
| | |
Authors:
|
Mitchell Kamrava; David Gius; Giovanna Casagrande; Elise Kohn |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Intramural; Review Date: 2009-11-05 |
Journal Detail:
|
Title: Ageing research reviews Volume: 10 ISSN: 1872-9649 ISO Abbreviation: Ageing Res. Rev. Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2010-12-21 Completed Date: 2011-03-31 Revised Date: 2012-01-04 |
Medline Journal Info:
|
Nlm Unique ID: 101128963 Medline TA: Ageing Res Rev Country: England |
Other Details:
|
Languages: eng Pagination: 62-70 Citation Subset: IM |
Copyright Information:
|
Published by Elsevier B.V. |
Affiliation:
|
Molecular Radiation Oncology Section, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, United States. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aging
/
physiology* Animals Caenorhabditis elegans / physiology Cardiovascular Diseases / physiopathology Cell Movement / physiology Drosophila melanogaster / physiology Humans Insulin / physiology* Insulin-Like Growth Factor Binding Protein 1 / physiology Mice Neoplasms / pathology* Signal Transduction / physiology Somatomedins / drug effects*, physiology* |
| Grant Support | |
ID/Acronym/Agency:
|
ZIA SC009374-18/SC/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Insulin; 0/Insulin-Like Growth Factor Binding Protein 1; 0/Somatomedins |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cost-Effectiveness of Alternative Imaging Strategies for the Diagnosis of Small-bowel Crohn's Diseas...
Next Document: HLA class II polymorphism in Latin American patients with multiple sclerosis.